Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

Weight loss goals may be at the forefront of many New Year's resolutions, which could push the exuberance for Eli Lilly (LLY) and Novo Nordisk (NVO) stock.

Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. Analyst ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...

Novo Nordisk (NVO) and Eli Lilly's (LLY) weight loss drugs lead Evaluate Pharma’s list of best-selling drugs projected for ...

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $83.34, denoting a -1.99% change from the preceding trading day.

Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Neutral ...

Novo Nordisk A/S (NYSE:NVO – Get Free Report) was upgraded by equities researchers at UBS Group from a “sell” rating to a ...

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” fourth ...

Novo Nordisk A/S (NVO) stock saw a modest uptick, ending the day at $85.64 which represents a slight increase of $2.30 or 2.76% from the prior close of $83.34. The stock opened at $85.51 and touched a ...